Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Sees Large Growth in Short Interest

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) saw a large growth in short interest in December. As of December 31st, there was short interest totalling 6,000,000 shares, a growth of 6.0% from the December 15th total of 5,660,000 shares. Currently, 31.2% of the shares of the stock are short sold. Based on an average daily volume of 250,800 shares, the short-interest ratio is currently 23.9 days.

Dianthus Therapeutics Price Performance

Shares of NASDAQ:DNTH traded up $0.79 during midday trading on Monday, reaching $20.00. 156,254 shares of the company’s stock were exchanged, compared to its average volume of 199,749. The firm’s 50 day simple moving average is $23.62 and its two-hundred day simple moving average is $26.40. The stock has a market cap of $592 million, a price-to-earnings ratio of -8.00 and a beta of 1.74. Dianthus Therapeutics has a fifty-two week low of $10.65 and a fifty-two week high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). The business had revenue of $2.17 million for the quarter, compared to analyst estimates of $1.07 million. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. Equities research analysts predict that Dianthus Therapeutics will post -2.61 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Dianthus Therapeutics

Institutional investors have recently bought and sold shares of the company. Quest Partners LLC grew its position in Dianthus Therapeutics by 112,400.0% in the 3rd quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock valued at $31,000 after acquiring an additional 1,124 shares in the last quarter. SG Americas Securities LLC grew its position in Dianthus Therapeutics by 9.2% in the 4th quarter. SG Americas Securities LLC now owns 9,653 shares of the company’s stock valued at $210,000 after acquiring an additional 814 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new position in Dianthus Therapeutics in the 2nd quarter valued at about $236,000. Fred Alger Management LLC grew its position in Dianthus Therapeutics by 52.5% in the 3rd quarter. Fred Alger Management LLC now owns 9,633 shares of the company’s stock valued at $264,000 after acquiring an additional 3,316 shares in the last quarter. Finally, Point72 DIFC Ltd purchased a new position in shares of Dianthus Therapeutics in the 2nd quarter valued at about $334,000. 47.53% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

DNTH has been the topic of a number of research reports. Raymond James upgraded Dianthus Therapeutics to a “moderate buy” rating in a report on Thursday, December 12th. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a research note on Monday, November 11th. Oppenheimer raised their target price on Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an “outperform” rating in a research note on Monday, November 11th. Finally, TD Cowen began coverage on Dianthus Therapeutics in a research note on Friday, December 20th. They issued a “buy” rating for the company. Eight analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $46.43.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.